Literature DB >> 30506281

Lymphopenia after induction chemotherapy correlates with incomplete surgical resection in patients with advanced ovarian cancer.

Yasunori Yoshino1, Ayumi Taguchi2, Maki Takao1, Tomoko Kashiyama1, Akiko Furusawa1, Masaya Uno1, Satoshi Okada1, Nao Kino1, Toshiharu Yasugi1.   

Abstract

BACKGROUND: Lymphopenia is associated with poor outcomes in patients with various cancers, but little is known about the prognostic impact of lymphopenia in patients with epithelial ovarian cancer (EOC) after induction chemotherapy (IC). This study investigated the prognostic significance of pre- and post-IC lymphopenia in patients with advanced EOC.
METHODS: We reviewed medical records of 68 patients with stage III/IV ovarian, fallopian tube, or peritoneal cancer treated with IC at our institution between 2009 and 2017. We assessed the associations of pre- and post-IC inflammatory markers, including lymphocyte counts, with several oncological outcomes, such as the implementation of interval debulking surgery (IDS), complete resection, progression-free survival (PFS), and overall survival (OS).
RESULTS: Lymphocyte counts increased significantly post-IC compared with the pre-IC values (P = 0.009). Pre-IC lymphopenia was observed in 27 patients (40%), whereas only 16 patients (24%) displayed lymphopenia post-IC (P = 0.020). Among several inflammatory markers, only post-IC lymphopenia was significantly associated with incomplete resection outcome during IDS (P = 0.012). Moreover, post-IC lymphopenia was significantly associated with poor PFS (log-rank test, P = 0.009), whereas pre-IC lymphopenia was associated with neither PFS nor OS.
CONCLUSIONS: Post-IC lymphopenia may predict incomplete resection during IDS and poor prognosis in patients with advanced EOC.

Entities:  

Keywords:  Epithelial ovarian cancer; Induction chemotherapy; Interval debulking surgery; Lymphopenia

Mesh:

Substances:

Year:  2018        PMID: 30506281     DOI: 10.1007/s10147-018-1374-4

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  35 in total

Review 1.  Ovarian surface epithelium: biology, endocrinology, and pathology.

Authors:  N Auersperg; A S Wong; K C Choi; S K Kang; P C Leung
Journal:  Endocr Rev       Date:  2001-04       Impact factor: 19.871

Review 2.  Optimal primary surgical treatment for advanced epithelial ovarian cancer.

Authors:  Ahmed Elattar; Andrew Bryant; Brett A Winter-Roach; Mohamed Hatem; Raj Naik
Journal:  Cochrane Database Syst Rev       Date:  2011-08-10

3.  The optimal debulking after neoadjuvant chemotherapy in ovarian cancer: proposal based on interval look during upfront surgery setting treatment.

Authors:  Takashi Onda; Hiroyuki Yoshikawa; Toshiharu Yasugi; Koji Matsumoto; Yuji Taketani
Journal:  Jpn J Clin Oncol       Date:  2009-10-10       Impact factor: 3.019

4.  Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide.

Authors:  Stuart A Grossman; Xiaobu Ye; Glenn Lesser; Andrew Sloan; Hetty Carraway; Serena Desideri; Steven Piantadosi
Journal:  Clin Cancer Res       Date:  2011-07-07       Impact factor: 12.531

5.  Hematological and iron-related analytes--reference data for persons aged 1 year and over: United States, 1988-94.

Authors:  Joseph G Hollowell; Onno W van Assendelft; Elaine W Gunter; Brenda G Lewis; Matthew Najjar; Christine Pfeiffer
Journal:  Vital Health Stat 11       Date:  2005-03

6.  Foxp3(+) cell infiltration and granzyme B(+)/Foxp3(+) cell ratio are associated with outcome in neoadjuvant chemotherapy-treated ovarian carcinoma.

Authors:  Martin Pölcher; Michael Braun; Nicolaus Friedrichs; Christian Rudlowski; Eva Bercht; Rolf Fimmers; Axel Sauerwald; Mignon-Denise Keyver-Paik; Kirsten Kübler; Reinhard Büttner; Walther C Kuhn; Juan-José Hernando
Journal:  Cancer Immunol Immunother       Date:  2010-01-20       Impact factor: 6.968

7.  Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma.

Authors:  Markéta Tomsová; Bohuslav Melichar; Iva Sedláková; Ivo Steiner
Journal:  Gynecol Oncol       Date:  2007-11-26       Impact factor: 5.482

8.  Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas.

Authors:  Isabelle Ray-Coquard; Claire Cropet; Martine Van Glabbeke; Catherine Sebban; Axel Le Cesne; Ian Judson; Olivier Tredan; Jaap Verweij; Pierre Biron; Inthidar Labidi; Jean-Paul Guastalla; Thomas Bachelot; David Perol; Sylvie Chabaud; Pancras C W Hogendoorn; Philippe Cassier; Armelle Dufresne; Jean-Yves Blay
Journal:  Cancer Res       Date:  2009-06-23       Impact factor: 12.701

9.  Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes.

Authors:  Katy Milne; Cheryl Alexander; John R Webb; Winnie Sun; Kristy Dillon; Steve E Kalloger; C Blake Gilks; Blaise Clarke; Martin Köbel; Brad H Nelson
Journal:  J Transl Med       Date:  2012-02-27       Impact factor: 5.531

Review 10.  The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis.

Authors:  M J M Gooden; G H de Bock; N Leffers; T Daemen; H W Nijman
Journal:  Br J Cancer       Date:  2011-05-31       Impact factor: 7.640

View more
  2 in total

1.  Early onset of severe lymphopenia during definitive radiotherapy correlates with mean body dose and predicts poor survival in cervical cancer.

Authors:  Li Yang; Zhiyuan Xu; Lingyu Ma; Qin Liu; Amy T Y Chang; Qian Wang; Jiandong Zha; Jinliang Zhang; Xiaoqin Jiang; Jingjing Zhang; Feng-Ming Spring Kong; Linlang Guo
Journal:  Cancer Biomark       Date:  2022       Impact factor: 4.388

2.  Peripheral Blood Classical Monocytes and Plasma Interleukin 10 Are Associated to Neoadjuvant Chemotherapy Response in Breast Cancer Patients.

Authors:  Javier Valdés-Ferrada; Natalia Muñoz-Durango; Alejandra Pérez-Sepulveda; Sabrina Muñiz; Irenice Coronado-Arrázola; Francisco Acevedo; Jorge A Soto; Susan M Bueno; Cesar Sánchez; Alexis M Kalergis
Journal:  Front Immunol       Date:  2020-07-09       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.